Literature DB >> 824327

Pneumonia caused by coliforms and Pseudomonas aeruginosa.

P Noone, B T Rogers.   

Abstract

The diagnosis and treatment of 20 hospital patients seen in the past year with proven pneumonia caused by coliforms and Pseudomonas aeruginosa are discussed. Predisposing factors and methods for improving laboratory and clinical diagnosis are analysed, the main problem being to discriminate between genuine pneumonia caused by these organisms and mere contamination of sputum samples resulting from colonization of the upper respiratory tract following broad-spectrum chemotherapy. Overall initial chemotherapy with gentamicin cured 75% (15 out of 20) of the patients in spite of unfavourable underlying pathology. Where gentamicin was given in adequate dosage, which in practice meant that dose which produced peak serum concentrations of 8 mug/ml or more, the cure rate was 91% (11 out of 12). In those patients achieving (measured) peak serum concentrations of less than 8 mug/ml the cure rate was only 33% (4 out of 12). These figures include four patients who failed to respond to doses of gentamicin producing peak concentrations of 5-0-6-0 mug/ml in each case. These patients responded promptly to higher doses (or accumulation), producing peak serum concentrations of 8 mug/ml or more and were then cured within three to five days. Toxicity from gentamicin was not observed in any patient. These results indicate that it is necessary to monitor gentamicin therapy by laboratory assay to ensure adequate dosage and that peak serum concentrations of 8 mug/ml or more are significantly correlated with successful treatment of pneumonia caused by coliforms and Ps. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 824327      PMCID: PMC476135          DOI: 10.1136/jcp.29.7.652

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Application of the Stomacher for rapid homogenization of sputum and the serial streak dilution method for quantitative culture.

Authors:  N J Mitchell; A R Harvey
Journal:  J Clin Pathol       Date:  1975-05       Impact factor: 3.411

2.  Occurrence of serious bacterial infections since introduction of antibacterial agents.

Authors:  M FINLAND; W F JONES; M W BARNES
Journal:  J Am Med Assoc       Date:  1959-08-29

3.  The effective use of gentamicin in life-threatening sepsis.

Authors:  P Noone; J R Pattison; D G Davies
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

4.  Use of a pancreatin-trypsin solution for the liquefaction of sputa for routine bacteriological examination.

Authors:  G A Rawlins
Journal:  J Clin Pathol       Date:  1968-07       Impact factor: 3.411

5.  The in-vitro activity of tobramycin compared with that of other aminoglycosides.

Authors:  P M Waterworth
Journal:  J Clin Pathol       Date:  1972-11       Impact factor: 3.411

6.  A simple and rapid method for the differentiation of the members of the genus Klebsiella.

Authors:  R Freeman
Journal:  J Clin Pathol       Date:  1974-11       Impact factor: 3.411

7.  Gentamicin in treatment of primary Gram-negative pneumonias.

Authors:  B G Gatmaitan; M M Carruthers; A M Lerner
Journal:  Am J Med Sci       Date:  1970-08       Impact factor: 2.378

8.  Quantitation of microorganisms in sputum.

Authors:  P W Monroe; H G Muchmore; F G Felton; J K Pirtle
Journal:  Appl Microbiol       Date:  1969-08

9.  A NEW SELECTIVE BLOOD AGAR MEDIUM FOR STREPTOCOCCUS PYOGENES AND OTHER HAEMOLYTIC STREPTOCOCCI.

Authors:  E J LOWBURY; A KIDSON; H A LILLY
Journal:  J Clin Pathol       Date:  1964-05       Impact factor: 3.411

10.  IDENTIFICATION AND CLINICAL SIGNIFICANCE OF KLEBSIELLA SPECIES IN CHEST INFECTIONS.

Authors:  J H DARRELL; A D HURDLE
Journal:  J Clin Pathol       Date:  1964-11       Impact factor: 3.411

View more
  7 in total

Review 1.  Klebsiella: taxonomy, nomenclature, and communication.

Authors:  J G Barr
Journal:  J Clin Pathol       Date:  1977-10       Impact factor: 3.411

Review 2.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

4.  Monitoring aminoglycoside use in patients with severely impaired renal function.

Authors:  P Noone; D F Beale; S S Pollock; M R Perera; I D Amirak; O N Fernando; J F Moorhead
Journal:  Br Med J       Date:  1978-08-12

5.  A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing.

Authors:  W E Evans; R H Taylor; S Feldman; W R Crom; G Rivera; G C Yee
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

6.  Unilateral pulmonary oedema and Pseudomonas pneumonia.

Authors:  J Uppington; M D Penney
Journal:  Postgrad Med J       Date:  1980-09       Impact factor: 2.401

7.  Unusual acute lupus hemophagocytic syndrome - a test of diagnostic criteria: a case report.

Authors:  Wijetunga Mudalige Udai Akalanka Wijetunga; Ravindra Laxman Satarasinghe; Balasuriya Mudiyanselage Dayananda; Ganhewage Kokila Darshani
Journal:  J Med Case Rep       Date:  2017-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.